Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Clorox Co    CLX

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

The Clorox Company : Refutes Silent Spring Institute's Study on Our Consumer Products

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/08/2012 | 03:26pm CEST

We have reviewed the findings of Silent Spring's study claiming some U.S. consumer products contain endocrine-disrupting and asthma-related ingredients.

Product safety is a top priority at The Clorox Company and our company guidelines prohibit using endocrine-disrupting ingredients in our products. For those household products containing fragrance ingredients some consider to be asthma related, these ingredients are present at such low concentrations they do not cause irritation or trigger asthma when used as directed.

Our highly skilled scientists evaluate each product's safety, efficacy and regulatory compliance before it makes it to store shelves. Our safety assessments begin with analysis of each of the materials that go into making the product. This includes consideration of short-term and long-term impact from all types of exposures, including incidental or accidental, and routes of exposure such as skin, eye, ingestion and inhalation. Our safety evaluation also includes the assessment of fragrances, dyes, and preservatives, and other proprietary ingredients, in our formulations.

Clorox voluntarily discloses all ingredients for our U.S. and Canadian household cleaning and disinfecting products through our industry-leading initiative, Ingredients Inside (www.IngredientsInside.com), which is available on our corporate web site and mobile platforms.

For more information on our product stewardship guidelines, visit http://www.thecloroxcompany..


share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CLOROX CO
05/22 CLOROX : Announces June 14 Webcast of Company Presentation at dbAccess Global Co..
05/22 CLOROX : Announces Time Change for Presentation at 33rd Annual Bernstein Strateg..
05/17 CLOROX : Kingsford Fires Up Petition To Make Barbecue Ribs America's National Fo..
05/09 DAILY DIVIDEND REPORT : Clx, leg, fds, ip, abc, lll
05/09 CLOROX : Increases Quarterly Dividend 5 Percent to 84 Cents Per Share
05/05 CLOROX : EPA Names Clorox Safer Choice Partner of the Year for Promotion of Safe..
05/04 CLOROX : Patent Issued for Closure (USPTO 9630753)
05/04 CLOROX : to Present at 33rd Annual Bernstein Strategic Decisions Conference on M..
05/03 CLOROX : DE/ Management's Discussion and Analysis of Financial Condition and Res..
05/03 CLOROX CO (NYSE : CLX) reported earnings of $1.31 per share beating Walls Street..
More news
Sector news : Household Products - NEC
05/26 Safe Sex - Chinese buy condom business as savvy youth spur demand
05/26 SAFE SEX : Chinese buy condom business as savvy youth spur demand
05/22 Cross-border M&A between U.S. and European firms at 10 year high
05/04 RECKITT BENCKISER : board sees off protest over safety scandal
04/24 J&J, Takeda among interested in Brazil's Hypermarcas, sources say
More sector news : Household Products - NEC
News from SeekingAlpha
05/24 What Do You Do When Social Security Falls Short Of Your Needs?
05/18 Vanguard Fund Destroys The S&P 500
05/17 COLGATE : Potential Buyout?
05/13 16 DIVIDEND INCREASES : May 8-12, 2017
05/10 Tracking The Parnassus Core Equity Fund - Q1 2017 Update
Advertisement
Financials ($)
Sales 2017 5 969 M
EBIT 2017 1 117 M
Net income 2017 697 M
Debt 2017 1 803 M
Yield 2017 2,40%
P/E ratio 2017 25,45
P/E ratio 2018 23,69
EV / Sales 2017 3,22x
EV / Sales 2018 3,10x
Capitalization 17 386 M
More Financials
Chart CLOROX CO
Duration : Period :
Clorox Co Technical Analysis Chart | CLX | US1890541097 | 4-Traders
Full-screen chart
Technical analysis trends CLOROX CO
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 17
Average target price 133 $
Spread / Average Target -1,4%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Benno O. Dorer Chairman & Chief Executive Officer
Dawn C. Willoughby Chief Operating Officer & Executive VP
Stephen M. Robb Chief Financial Officer & Executive Vice President
Manjit Singh Chief Information Officer & Senior Vice President
Robert W. Matschullat Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CLOROX CO12.47%17 386
RECKITT BENCKISER GROU..14.28%70 562
UNILEVER INDONESIA TBK..--.--%27 296
CHURCH & DWIGHT CO., I..15.64%12 737
LION CORP16.70%6 004
KOBAYASHI PHARMACEUTIC..30.54%4 817
More Results